ArticleJACC. Case reports2026
Transcatheter Edge-to-Edge Repair After Patent Foramen Ovale and Atrial Septal Defect Closure.
Article in JACC. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTransseptal puncture is essential for transcatheter edge-to-edge repair (TEER) but is challenging in patients with previously implanted septal closure devices. CASE SUMMARY: A 79-year-old woman with prior transcatheter closure of both a patent foramen ovale and an atrial septal defect developed severe degenerative mitral regurgitation (MR). Transseptal access was considered difficult due to the 2 closure devices. However, chronic MR caused enlargement of the left atrium and interatrial septum, creating a narrow but feasible puncture zone. Using the VersaCross system, transseptal puncture was achieved, allowing TEER completion. DISCUSSION: Left atrial and septal enlargement from MR can create puncturable spaces despite prior septal closure devices. The VersaCross system enables controlled septal crossing, expanding the feasibility of TEER in anatomically complex patients. TAKE-HOME MESSAGE: Chronic atrial remodeling secondary to severe MR may facilitate transseptal access after septal closure, and the VersaCross system can support safe puncture in challenging TEER cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.